Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Investors shaken by PTC's briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14% premarket

Published 09/26/2017, 09:22 AM
© Reuters.  Investors shaken by PTC's briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14% premarket
SRPT
-
PTCT
-
  • PTC Therapeutics (NASDAQ:PTCT) slumps 14% premarket on increased volume in apparent response to the release of briefing documents ahead of Thursday's FDA Advisory Committee review of its marketing application for Duchenne muscular dystrophy (DMD) candidate Translarna (ataluren).
  • This a rare case of an advisory committee review of an application "filed-over-protest" in which the applicant insists that the FDA further review the data that was initially regarded as insufficient to support approval. On two prior occasions, 2011 and 2016, the FDA rejected the company's application under "Refuse to File" which means the filing was not complete enough to permit a substantive review.
  • The present situation is the result of the FDA's controversial approval of Sarepta Therapeutics' (NASDAQ:SRPT) application for EXONDYS 51 in September 2016 that many observers perceived lacked sufficient proof that the drug works.
  • FDA briefing doc
  • Addendum to FDA briefing doc
  • Errata to FDA briefing doc
  • PTC briefing doc
  • Addendum to PTC briefing doc
  • Now read: Sarepta Belongs Closer To After Golodirsen Data


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.